{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T21:52:22Z","timestamp":1775512342568,"version":"3.50.1"},"reference-count":38,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:00:00Z","timestamp":1610064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Even though 80% of patients with High-Grade Serous Ovarian Cancer respond to standard first-line chemotherapy, a majority of them could relapse in the following five years due to a resistance to platinum. Human Epididymis protein 4 (HE4) is one of the most promising markers in predicting platinum therapy response. This pilot study aims to evaluate the potential role of HE4 value in predicting chemotherapy response in BRCA mutated patients and in BRCA wild-type (non-mutated) ones. We selected 69 patients, affected by High-Grade Serous Ovarian Cancer, and optimally debulked and submitted to standard chemotherapy protocols. HE4 was dosed during every chemotherapy course. Patients were classified as platinum-resistant and platinum-sensitive. According to BRCA mutation test, patients were further divided into BRCA wild-type (53 patients), and BRCA mutated (16 patients). 35 patients out of 69 (52%) were platinum-sensitive (recurrence &gt; 12 months), while 33 patients (48%) were platinum-resistant (recurrence &lt; 12 months). Thus, in the total population, HE4 performed as a marker of chemosensitivity with a sensibility of 79% and a specificity of 97%. In the BRCA WT group, 23 patients out of 53 (43%) were platinum-sensitive, while 30 patients out of 53 (57%) were platinum-resistant. In the BRCA WT group, HE4 performed as a predictive marker of chemosensitivity with a sensibility of 80% and a specificity of 100%. In the BRCA mutated group, 13 patients out of 16 (82%) were platinum-sensitive, while 3 patients (18%) were platinum-resistant. In the BRCA mutated group, HE4 performed as a predictive marker of chemosensitivity in all patients. The ability to detect platinum-resistant patients before tumor relapse probably could open new therapeutic scenarios.<\/jats:p>","DOI":"10.3390\/biomedicines9010055","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T19:55:56Z","timestamp":1610308556000},"page":"55","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Role of BRCA Mutation and HE4 in Predicting Chemotherapy Response in Ovarian Cancer: A Retrospective Pilot Study"],"prefix":"10.3390","volume":"9","author":[{"given":"Francesco","family":"Plotti","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, University \u2018\u2018Campus Bio-Medico\u2019\u2019 of Rome, Via Alvaro del Portillo, 200-00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Terranova","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University \u2018\u2018Campus Bio-Medico\u2019\u2019 of Rome, Via Alvaro del Portillo, 200-00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Guzzo","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University \u2018\u2018Campus Bio-Medico\u2019\u2019 of Rome, Via Alvaro del Portillo, 200-00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"De Cicco Nardone","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University \u2018\u2018Campus Bio-Medico\u2019\u2019 of Rome, Via Alvaro del Portillo, 200-00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Luvero","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University \u2018\u2018Campus Bio-Medico\u2019\u2019 of Rome, Via Alvaro del Portillo, 200-00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Bartolone","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University \u2018\u2018Campus Bio-Medico\u2019\u2019 of Rome, Via Alvaro del Portillo, 200-00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Dionisi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University \u2018\u2018Campus Bio-Medico\u2019\u2019 of Rome, Via Alvaro del Portillo, 200-00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Benvenuto","sequence":"additional","affiliation":[{"name":"Unit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, 00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Fabris","sequence":"additional","affiliation":[{"name":"Unit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, 00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Ciccozzi","sequence":"additional","affiliation":[{"name":"Unit of Medical Statistics and Molecular Epidemiology, University Campus Bio-Medico of Rome, 00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9254-5790","authenticated-orcid":false,"given":"Violante","family":"Di Donato","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Obstetrics and Urology, Policlinico Umberto I, \u201cSapienza\u201d University of Rome, 00161 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluigi Benedetti","family":"Panici","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Obstetrics and Urology, Policlinico Umberto I, \u201cSapienza\u201d University of Rome, 00161 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Angioli","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University \u2018\u2018Campus Bio-Medico\u2019\u2019 of Rome, Via Alvaro del Portillo, 200-00128 Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bpobgyn.2016.08.006","article-title":"Epidemiology of epithelial ovarian cancer","volume":"41","author":"Webb","year":"2017","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Lisio, M.-A., Fu, L., Goyeneche, A.A., Gao, Z.-H., and Telleria, C.M. (2019). High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040952"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1200\/JCO.2016.66.8178","article-title":"Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis from the Ovarian Cancer Cohort Consortium","volume":"34","author":"Wentzensen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1471-0528.1998.tb10148.x","article-title":"A systematic review and meta-analysis of family history and risk of ovarian cancer","volume":"105","author":"Stratton","year":"1998","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2741\/4230","article-title":"The Breast Cancer Susceptibility Genes (BRCA) in Breast and Ovarian Cancers","volume":"19","author":"Paul","year":"2014","journal-title":"Front. Biosci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bpobgyn.2016.10.017","article-title":"Hereditary Ovarian Cancer and Risk Reduction","volume":"41","author":"Andrews","year":"2017","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2011). Integrated genomic analyses of ovarian carcinoma. Nature, 474, 609\u2013615.","DOI":"10.1038\/nature10166"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1093\/annonc\/mdw142","article-title":"BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer","volume":"27","author":"Moschetta","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/annonc\/mdq628","article-title":"Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients","volume":"22","author":"Vencken","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/oxfordjournals.annonc.a010602","article-title":"Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group study","volume":"7","author":"Rustin","year":"1996","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000217982","article-title":"Specificity and Affinity of 26 Monoclonal Antibodies against the CA 125 Antigen: First Report from the ISOBM TD-1 Workshop","volume":"17","author":"Nustad","year":"1996","journal-title":"Tumor Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1006\/gyno.2002.6689","article-title":"Specific Keynote: Ovarian Cancer Risk Assessment and the Potential for Early Detection","volume":"88","author":"Urban","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13048-019-0503-7","article-title":"Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review","volume":"12","author":"Dochez","year":"2019","journal-title":"J. Ovarian Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/14737140.2017.1360138","article-title":"The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: A systematic review","volume":"17","author":"Scaletta","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ygyno.2012.11.040","article-title":"Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcino-ma?","volume":"128","author":"Angioli","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000446238","article-title":"Is the risk of ovarian malignancy algorithm better than other tests for pre-dicting ovarian malignancy in women with pelvic masses?","volume":"82","author":"Yanaranop","year":"2017","journal-title":"Gynecol. Obstet. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1746-1596-8-11","article-title":"Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response","volume":"8","author":"Hamed","year":"2013","journal-title":"Diagn. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1097\/IGC.0b013e3182681cfd","article-title":"The Prognostic and Predictive Value of Combined HE4 and CA-125 in Ovarian Cancer Patients","volume":"22","author":"Steffensen","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/apm.12625","article-title":"HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithe-lial ovarian cancer","volume":"124","author":"Nedergaard","year":"2016","journal-title":"APMIS"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13048-016-0270-7","article-title":"Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after ne-oadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer","volume":"9","author":"Pelissier","year":"2016","journal-title":"J. Ovarian Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1038\/srep03574","article-title":"HE4 (WFDC2) gene overexpression promotes ovarian tumor growth","volume":"4","author":"Moore","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3892\/or.2014.3549","article-title":"Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells","volume":"33","author":"Wang","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_23","first-page":"830","article-title":"Membranous expressions of Lewis y and CAM-DR-related markers are independent factors of chemotherapy resistance and poor prognosis in epithelial ovarian cancer","volume":"5","author":"Zhu","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13048-016-0240-0","article-title":"HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells","volume":"9","author":"Ribeiro","year":"2016","journal-title":"J. Ovarian Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/jog.13181","article-title":"Role of human epididymis protein 4 in chemoresistance and prognosis of epithelial ovarian cancer: Role of HE4 in ovarian cancer","volume":"43","author":"Lee","year":"2017","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"889","DOI":"10.31083\/j.ejgo.2020.06.2239","article-title":"Role of human epididymis protein 4 (HE4) as predictor of response to platinum based chemotherapy: A systematic review of literature","volume":"41","author":"Plotti","year":"2020","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","article-title":"Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women with Advanced Epithelial Ovarian Cancer: Three-Year Results","volume":"92","author":"Piccart","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2000.18.17.3084","article-title":"Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian Cancer","volume":"18","author":"Neijt","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with opti-mally resected stage III ovarian cancer: A Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","article-title":"Advances in ovarian cancer therapy","volume":"81","author":"Cortez","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/IGC.0000000000001115","article-title":"Novel Therapeutics for Ovarian Cancer: The 11th Biennial Rivkin Center Ovarian Cancer Research Symposium","volume":"27","author":"Johnson","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/ijgc-2019-000211","article-title":"Role of human epididymis protein 4 (HE4) in detecting recurrence in CA125 negative ovarian cancer patients","volume":"29","author":"Plotti","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s13277-012-0471-7","article-title":"Does HE4 have a role as biomarker in the recurrence of ovarian cancer?","volume":"33","author":"Plotti","year":"2012","journal-title":"Tumor Biol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/IGC.0000000000000181","article-title":"Prognostic Value of Serum HE4 Levels and Risk of Ovarian Malignancy Algorithm Scores at the Time of Ovarian Cancer Diagnosis","volume":"24","author":"Kaijser","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.3892\/ol.2016.4533","article-title":"Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer","volume":"11","author":"Steffensen","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1158\/1078-0432.CCR-13-1376","article-title":"REM (risk of endometrial malignancy): A proposal for a new scoring system to evaluate risk of endometrial ma-lignancy","volume":"19","author":"Angioli","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Li, M., Balch, C., Montgomery, J.S., Jeong, M., Chung, J.H., Yan, P., Huang, T.H.M., Kim, S., and Nephew, K.P. (2009). Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med. Genom., 2.","DOI":"10.1186\/1755-8794-2-34"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/1\/55\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:08:52Z","timestamp":1760159332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/1\/55"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,8]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["biomedicines9010055"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines9010055","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,8]]}}}